---
document_datetime: 2025-10-15 10:43:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ahzantive-epar-all-authorised-presentations_en.pdf
document_name: ahzantive-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8011961
conversion_datetime: 2025-12-20 09:24:49.942869
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number    | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging      | Content (concentration)   | Pack size            |
|-------------------|-------------------|------------|------------------------|---------------------------|--------------------------|---------------------------|----------------------|
| EU/1/24/1888/ 001 | Ahzantive         | 40 mg/ml   | Solution for injection | Intravitreal use          | Vial (glass)             | 0.1 ml                    | 1 vial               |
| EU/1/24/1888/ 002 | Ahzantive         | 40 mg/ml   | Solution for injection | Intravitreal use          | Pre-filled syringe (COP) | 0.09 ml                   | 1 pre-filled syringe |